Liam Ratcliffe - 27 May 2021 Form 4 Insider Report for Passage BIO, Inc. (PASG)

Reporting relationship: Director
Issuer ticker: PASG
Reported as of: 27 May 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 May 2021, 17:58:14 UTC
Next SEC filing: 10 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ Edgar Cale, Attorney-in-Fact

Key filing fact

Liam Ratcliffe filed Form 4 for Passage BIO, Inc. (PASG) on 28 May 2021.

Key facts

This page summarizes Liam Ratcliffe's Form 4 filing for Passage BIO, Inc. (PASG).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 May 2021, 17:58.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PASG transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +16,918
Change %
Price: $0.000000
Shares after: 16,918
Date: 27 May 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,918
Exercise price: $13.83
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.